NEW YORK (GenomeWeb News) — EMD Biosciences will use Starpharma’s dendrimers for DNA and siRNA transfection research, EMD said today.
Under the terms of the license and supply agreement, Starpharma’s US subsidiary Dendritic Nanotechnologies will supply EMD with the Priostar technology in exchange for royalties and milestones.
DNT will retain the full rights to use Priostarall for in vivo transfection research.
Lisa Johnson, EMD’s vice president of corporate development, said the company plans to develop new transfect ion reagents, which EMD will market under the Novagen brand.
Johnson said the company sees the transfection reagent market as “rapidly growing,” and said EMD plans to make this technology “a foundation for future product platforms."
Financial terms of the agreement were not released.